Breast implant company Sientra saw its valuation cut in half on news that its contract manufacturer Silimed has had its CE mark suspended by the U.K. Department of Health. The move came after German regulators conducted an inspection of a Brazilian manufacturing plant--and regulators found that "the surfaces of some implants were contaminated with particles."
Continuing to spread its wings, India's Lupin now has a toehold in the Brazil market by buying Medquímica Indústria Farmacêutica, producer of branded, generic and over-the-counter drugs.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Sanofi has made a big investment in Brazil, buying the nation's largest generics manufacturer, Genfar, in 2012 to get a stronger foothold not only in human drugs but also in animal health. It's now expanding its manufacturing operations there for its Merial animal health operation.
Conspiring to keep distributors from working with generic drugmakers is a no-no in Brazil, and the country's antitrust regulator is fining Merck KGaA for allegedly doing just that. And while the move harkens back to a meeting that happened 5 years ago, it's reflective of actions taken more recently by regulators in the U.S. and EU.
Diversified conglomerate Danaher emphasized organic growth rather than acquisitions at a recent investor meeting. That's despite much speculation on its M&A appetite following the Medtronic announcement that it will acquire Covidien.
Eli Lilly has hotly denied and intends to fight the findings of a court in Brazil that could cost it nearly half a billion dollars to cover medical costs for former employees.
Eli Lilly in 2003 sold an antibiotics manufacturing plant in Cosmopolis, Brazil, to Italy's ACS Dobfar. But the fact that it has been more than a decade since Eli Lilly owned the facility has not kept the company from being ordered to pay $450 million to cover medical costs of dozens of plant employees for health problems they said came from exposure to hazardous materials.
Serving emerging markets generally requires local production--and that means investments in upgrades. That is the phase Eli Lilly is in with a packaging operation in São Paulo, Brazil.
Two of the biggest players in Brazil's medical diagnostics industry are likely to confront major changes in the coming months-- both worth noting as global competitors seek to enter one of the largest emerging markets around.